Management of Systemic Cardiotoxicity Associated with Antidepressant Use in Patients with Depressive Disorders: A

Omar Anwar Saleh Al Nakhebi1, Raluka Albu-Kalinovic1, Adela Bosun1

  • 1Doctoral School, University of Medicine and Pharmacy Victor Babes Timisoara, 300041 Timisoara, Romania.

PubMed

Insights

Antidepressant use is linked to cardiotoxicity, a serious adverse effect. A multidisciplinary approach is crucial for managing and protecting patients from these cardiac risks.

Area of Science:

  • Cardiology
  • Psychiatry
  • Pharmacology

Background:

  • Depression significantly impacts global health and quality of life.
  • Antidepressants are vital for depression treatment but carry risks, including cardiotoxicity.
  • Understanding antidepressant-induced cardiotoxicity is critical for patient safety.

Purpose of the Study:

  • To systematically review and analyze the correlation between antidepressant use and cardiotoxicity.
  • To evaluate the importance of a multidisciplinary approach in managing patients at risk.
  • To inform clinical practice regarding antidepressant-induced cardiac adverse effects.

Main Methods:

  • Systematic literature search adhering to PRISMA guidelines.
  • Inclusion of twenty studies for quantitative analysis.
  • Risk of bias assessment using the Joanna Briggs Institute critical appraisal tool.

Main Results:

  • A significant correlation was identified between antidepressant intake and cardiotoxicity.
  • The necessity of a multidisciplinary strategy for patient protection was highlighted.
  • Pathophysiological mechanisms and therapeutic options were explored.

Conclusions:

  • Effective management of antidepressant-induced cardiotoxicity necessitates understanding its mechanisms.
  • Critical evaluation of therapeutic strategies is essential for clinical practice.
  • A comprehensive approach is vital for mitigating cardiac risks associated with antidepressants.

Related Concept Videos

Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
398
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
339
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405